Document Detail

Intravenous pamidronate in the treatment of transient osteoporosis of the hip.
MedLine Citation:
PMID:  12110419     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the efficacy of intravenous pamidronate in patients with transient osteoporosis of the hip (TOH). Thirteen men and three women (mean age 38.3 years, range 30-49) were recruited. The diagnosis was made by means of radiographs, bone scintigraphy, and magnetic resonance imaging (MRI). Pamidronate (45 mg) was intravenously administered three times, once every third day. The outcome measures included a clinical assessment using a pain visual analog scale (VAS; range 0-100), and the WOMAC functional impairment score (FUI; range 0-100). The bone mineral density (BMD) of the total hip and femoral neck was measured using dual-energy X-ray absorptiometry (DXA). Clinical assessments were made before treatment (T(0)) and 1 month later (T(1)), and the densitometric measurements at T(0), and then after 2 (T(2)) and 4 months (T(4)). A further MRI scan was made 3 months after treatment. In comparison to the unaffected side, there was a significant decrease at T(0) in the BMD of both the total hip (median 16.6%, range 8.5%-29.1%, p < 0.00001) and femoral neck (median 22.5%, range 12.0%-34.2%, p < 0.00001). By T(1), both VAS and FUI had decreased significantly (p < 0.00001). By T(2), the total hip and femoral neck BMD had increased by 10.9% (range 2.7%-23.6%, p < 0.00001) and 12.3% (range 7.8%-26.9%, p < 0.00001), respectively, and all patients were asymptomatic. By T(3), the MRI findings had normalized in all patients and, at T(4), there was a further increase in BMD. None of the patients experienced symptom relapse during the follow-up of 39.5 +/- 17.7 months. These results suggest that a short course of pamidronate is effective in treating TOH, and leads to a prompt and long-lasting recovery.
M Varenna; F Zucchi; L Binelli; S Failoni; M Gallazzi; L Sinigaglia
Related Documents :
15041489 - Therapeutic ultrasound to stimulate osteoconduction; a placebo controlled single blind ...
18044089 - Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopaus...
8442439 - Rapid, divergent changes in spinal and forearm bone density following short-term intrav...
19073509 - The effect of tamoxifen or exemestane on bone mineral density during the first 2 years ...
19301089 - The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: ...
7801499 - Cancellous bone grafting in the treatment of bovine septic physitis.
24795269 - A preliminary report of acute and subacute arthroscopic repair of the radial ulnohumera...
3335109 - Revision total knee arthroplasty for aseptic failure.
18021979 - Operative treatment of endometrial hyperplasia in kidney graft recipients: report of se...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Bone     Volume:  31     ISSN:  8756-3282     ISO Abbreviation:  Bone     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-07-11     Completed Date:  2003-01-15     Revised Date:  2006-03-08    
Medline Journal Info:
Nlm Unique ID:  8504048     Medline TA:  Bone     Country:  United States    
Other Details:
Languages:  eng     Pagination:  96-101     Citation Subset:  IM    
Department of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Density / drug effects,  physiology
Diphosphonates / pharmacology,  therapeutic use*
Hip / pathology*
Infusions, Intravenous
Middle Aged
Osteoporosis / drug therapy*,  pathology*
Statistics, Nonparametric
Reg. No./Substance:
0/Diphosphonates; 40391-99-9/pamidronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Correlation of bone mineral density with strength and microstructural parameters of cortical bone in...
Next Document:  Reduced bone mineral density in postmenopausal women self-reporting premenopausal wrist fractures.